Church & Dwight Reports Strong Q1 2026 Results, Reiterates Full-Year Outlook

Key Takeaways for Investors

• Q1 Net Sales: \$1.47 billion (+0.2% YoY), outperforming guidance of -1%.
• Organic Sales: Up 5.0% (Domestic: +5.4%, International: +3.7%, Specialty Products: +3.1%).
• Adjusted Gross Margin: 46.4%, up 130 basis points YoY.
• Adjusted EPS: \$0.95 (+4.4% YoY), beating guidance of \$0.92.
• Cash from Operations: \$174.8 million for Q1; full-year guidance reaffirmed at \$1.15 billion.
• Full-Year 2026 Outlook: Organic sales growth 3%–4%; reported sales -1.5% to -0.5% (due to portfolio actions); adjusted EPS growth 5%–8%; capital expenditures expected at \$130 million (2% of sales).
• Innovation Pipeline: New launches in Therabreath, Arm & Hammer, Hero, and Trojan brands expected to drive 50% of organic growth in 2026.
• Strategic Acquisitions: Recent additions like Touchland, Therabreath, and Hero are fueling growth, but Touchland’s SG&A and amortization will pressure H1 results.
• Risks: Ongoing Middle East volatility, inflation, and transportation costs pose potential headwinds but are expected to be offset by operational strengths.

Detailed Financial Performance

Q1 2026 Results

• Net Sales: \$1,469.3 million, a slight increase of 0.2% YoY, beating outlook due to stronger organic sales (+5.0%).
• Consumer Domestic: Net sales \$1,117.7 million, down 1.1% due to 2025 portfolio actions but organic sales up 5.4% (volume +5.5%).
• Consumer International: Net sales \$273.9 million (+4.6%); organic sales +3.7% (volume +5.3%). Growth led by Therabreath, Hero, and Batiste brands.
• Specialty Products: Net sales \$77.7 million (+3.1%); organic sales +3.1% (volume +2.0%, price/mix +1.1%).
• Gross Margin: Increased 140 bps to 46.4% (adjusted gross margin up 130 bps), driven by higher volume, productivity, favorable mix, and portfolio actions.
• Operating Income: \$291.0 million (adjusted: \$302.6 million, up \$0.1 million YoY). Higher gross margin offset by increased marketing and Touchland-related SG&A/amortization.
• Marketing Expense: \$139.4 million (9.5% of sales, up 20 bps YoY) as the company continues to support innovation-led growth.
• SG&A: \$251.0 million, including \$6.3 million Touchland restricted stock; adjusted SG&A \$239.4 million (16.3% of sales, up 110 bps YoY).
• Net Income: \$216.3 million (\$0.91 per diluted share; adjusted EPS \$0.95, +4.4% YoY).
• Cash Flow: Operations generated \$174.8 million (down \$10.9 million YoY) as higher cash earnings were offset by increased working capital to support organic growth; capex at \$31.9 million (up \$15.4 million YoY).
• Balance Sheet: Cash \$503.4 million; total debt \$2.2 billion; robust liquidity for continued acquisitions and organic investments.

2026 Innovation Pipeline: Major Product Launches

• Therabreath: New toothpaste line (fresh breath, whitening, gum health) with strong consumer reviews (4.6/5 average rating).
• Arm & Hammer Cat Litter: Dual Defense with Microban Clump, providing dual odor and antimicrobial protection, targeting germ-conscious consumers.
• Hero: Launching three new acne cleansers (mid-2026), plus Mighty Shield “liquid to patch” film for invisible blemish protection.
• Arm & Hammer Laundry: Baking Soda Fresh detergent (10x baking soda), expanding value tier and responding to demand for value and cleaning efficacy.
• Trojan: “G.O.A.T.” condoms (ultra-flex, non-latex, highest softness, 4.7-star rating on Amazon since Q4 2025 launch).

Full-Year 2026 Outlook: Guidance and Strategic Priorities

• Organic Sales Growth: 3%–4% expected for 2026; Q2 organic growth of ~3% forecasted.
• Reported Sales: Down 1.5% to 0.5% due to 2025 portfolio actions (divestitures).
• Gross Margin: 100 bps full-year expansion expected, with H1 facing transportation cost headwinds (Q2 gross margin expansion of 50 bps expected).
• Marketing Spend: To remain at ~11% of sales, consistent with historical model.
• SG&A: Will remain elevated in H1 2026 due to Touchland acquisition and investment in new growth initiatives, ecommerce, and international expansion.
• Tax Rate: Adjusted effective tax rate guided to ~21.5% (down from 22.3% in 2025).
• EPS: Reported EPS expected to rise 18%–22%; adjusted EPS to rise 5%–8%, with growth skewed to H2 2026 due to H1 Touchland amortization, SG&A, and marketing spend. Adjusted EPS guidance excludes a 1% headwind from ERP upgrade costs.
• Cash Flow: Operations to generate ~\$1.15 billion; capex of ~\$130 million (2% of sales).
• Acquisitions: Continued focus on fast-moving consumable products; recent examples (Therabreath, Hero, Touchland) cited as models.

Key Risks and Potential Shareholder Impact

• Macro Risks: Middle East conflict causing inflation and transportation cost pressures; management expects to offset these with mix, volume, and productivity gains.
• Portfolio Actions: 2025 divestitures are dragging reported sales but improving portfolio quality; \$400 million in lost revenue and stranded costs are being offset through growth and margin expansion.
• Acquisition Integration: Touchland is expected to drive future growth but will temporarily elevate SG&A and amortization expenses in H1 2026.
• Strong Liquidity: Ample cash and borrowing capacity to fund future acquisitions and innovation.
• E-commerce Growth: Online sales now represent 24% of total consumer sales and continue to grow.

Shareholder-Relevant, Potentially Price-Sensitive Information

• Q1 beat on sales, gross margin, and EPS versus guidance, with strong organic growth across all divisions.
• Full-year 2026 guidance reaffirmed despite macro headwinds; management confidence in offsetting inflation and transportation costs.
• New product launches expected to drive half of organic growth in 2026—a positive for future sales and market share.
• Elevated SG&A from Touchland acquisition and ERP project costs will weigh on H1 EPS, but H2 expected to deliver majority of earnings growth.
• Continued active M&A strategy, with robust balance sheet, could lead to further inorganic growth or surprise announcements.
• Risks from global geopolitical instability, inflation, and supply chain remain, but are actively managed.

Company Overview and Sustainability Commitments

Church & Dwight (NYSE: CHD), founded in 1846, is the leading U.S. producer of sodium bicarbonate (baking soda) and manufacturer of major consumer brands including ARM & HAMMER, TROJAN, OXICLEAN, FIRST RESPONSE, NAIR, ORAJEL, XTRA, WATERPIK, ZICAM, THERABREATH, HERO, and TOUCHLAND. The company has a longstanding commitment to sustainability, with recycled packaging since the early 1900s, early adoption of phosphate-free detergents, and recent recognition from Time, Newsweek, USA Today, EPA, and FTSE4Good for environmental performance.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Financial data referenced herein is based on Church & Dwight’s Q1 2026 earnings press release and related documents. Investors should review official filings and consult with a financial advisor before making investment decisions. Forward-looking statements are subject to risks and uncertainties as outlined in the company’s SEC filings.

View CHURCH & DWIGHT CO INC /DE/ Historical chart here